Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.60 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20371519 | 0.86 | CA2 (0.56) | PTGS2PTGS1DRD1 | |
| SCHEMBL23501943 | 0.84 | DRD1 (0.52) | PTGS2PTGS1DRD1ATR | |
| SCHEMBL20371667 | 0.81 | IKBKB (0.48) | — | |
| SCHEMBL15730118 | 0.80 | PTGS2 (0.67) | PTGS2PTGS1DRD1 | |
| SCHEMBL20371609 | 0.78 | SYK (0.46) | — | |
| SCHEMBL8150056 | 0.78 | PTGS1 (0.42) | PTGS2PTGS1 | |
| SCHEMBL6170026 | 0.78 | PTGS2 (0.63) | PTGS2PTGS1DRD1 | |
| SCHEMBL5350907 | 0.78 | PTGS2 (0.63) | PTGS2PTGS1DRD1 | |
| SCHEMBL25339185 | 0.78 | PTGS2 (0.63) | PTGS2PTGS1DRD1 | |
| SCHEMBL17066980 | 0.77 | TDP1 (0.41) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | PTGS2 2700/4885PTGS1 1484/4885MTOR 676/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | PTGS2 2700/4885PTGS1 1484/4885MTOR 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.